Thursday, July 3, 2025 7/3/2025

Developing non-anticoagulant recombinant heparin for treating the COPD Pathogenic Triad

Award Number: R43HL162135
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/05/2022
PERIOD OF PERFORMANCE END DATE: 05/31/2024

Group Awards By:

View Award Description

Developing non-anticoagulant recombinant heparin for treating the COPD Pathogenic Triad - PROJECT SUMMARY This proposal describes a novel strategy to treat emphysema in COPD (chronic obstructive pulmonary disease) using uniquely tailored heparan sulfate produced from genetically engineered mammalian cells. Emphysema is a major component of COPD, a disease that afflicts up to 5% of the population and is the 4th leading cause of death in the US. There is currently no drug that has proven efficacious to cure or delay progression of the disease. While targeted therapies have shown little clinical benefit, heparin has multi-point inhibitory activity against the three major drivers of disease progression (proteases, oxidative stress and inflammation) and can be inhaled for local treatment. Heparin’s usefulness is limited by its anticoagulant activity. TEGA Therapeutics’ recombinant heparan sulfate production technology enables targeted elimination of 3-O-sulfate groups that are essential for anticoagulant activity while maintaining anti-elastolytic, anti- oxidative and anti-inflammatory properties. Mammalian cell lines that produce heparan sulfate without 3-O- sulfate will be genetically engineered to improve inhibition of emphysema drivers. The products will then be tested to evaluate their ability to inhibit proteases, oxidative stress and inflammatory mediators in vitro. Finally, the efficacy of the top candidate will be assessed through orotracheal delivery in a rat model of emphysema. The resulting product will be further developed as an inhalable drug in Phase II through bioprocess development, formulation, toxicology studies and pharmacokinetic studies. Success in this endeavor will yield a clinical drug that limits the progression of emphysema and increases the duration and quality of life for patients. It would likely also be useful for other chronic pulmonary diseases including cystic fibrosis and alpha- 1 antitrypsin deficiency.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	TEGA THERAPEUTICS INC	3550 GENERAL ATOMICS CT STE G02-102	SAN DIEGO	CA	92121	SAN DIEGO	USA	Lung Diseases Research	001	1	9/24/2024	NEW	$0
2024	2022	TEGA THERAPEUTICS INC	3550 GENERAL ATOMICS CT STE G02-102	SAN DIEGO	CA	92121	SAN DIEGO	USA	Lung Diseases Research	000	1	2/5/2024	NEW	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2022	TEGA THERAPEUTICS, INC.	3550 GENERAL ATOMICS CT STE G02-102	SAN DIEGO	CA	92121	SAN DIEGO	USA	Lung Diseases Research	000	1	2/15/2023	NEW	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $321,866 )
2022	2022	TEGA THERAPEUTICS, INC.	3550 GENERAL ATOMICS CT STE G02-102	SAN DIEGO	CA	92121	SAN DIEGO	USA	Lung Diseases Research	000	1	2/4/2022	NEW	$321,866
														Subtotal = $321,866

Grand Total All Awards = $321,866

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Developing non-anticoagulant recombinant heparin for treating the COPD Pathogenic Triad

Award Number: R43HL162135

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/05/2022

PERIOD OF PERFORMANCE END DATE: 05/31/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer